Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value

Daniel Ahn, Andrew H. Ko, Neal J. Meropol, Tanios Bekaii-Saab

Research output: Contribution to journalReview article

Abstract

Pancreatic cancer remains the fourth leading cause of cancer deaths in the United States with a dismal prognosis and a 5-year survival of less than 5% across all stages.(1) In 2014, there were approximately 46,420 new cases of pancreatic cancer with only 9% of patients having localized disease.(2) Given that the vast majority of patients present with advanced disease, much of the focus for drug development has been in the metastatic setting, which is evident with the advent of two combination chemotherapy regimens for this indication. Although conventional cytotoxic chemotherapy remains the standard of care, an ongoing search for novel therapeutic approaches continues. We will highlight several new approaches here, with a particular emphasis on immunotherapeutic strategies. We will also introduce concepts regarding the potential economic effects associated with the development and implementation of new treatments in pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)e222-e227
JournalAmerican Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Standard of Care
Combination Drug Therapy
Cause of Death
Therapeutics
Economics
Drug Therapy
Survival
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{557221370b3948e0a2deff47ef316604,
title = "Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value",
abstract = "Pancreatic cancer remains the fourth leading cause of cancer deaths in the United States with a dismal prognosis and a 5-year survival of less than 5{\%} across all stages.(1) In 2014, there were approximately 46,420 new cases of pancreatic cancer with only 9{\%} of patients having localized disease.(2) Given that the vast majority of patients present with advanced disease, much of the focus for drug development has been in the metastatic setting, which is evident with the advent of two combination chemotherapy regimens for this indication. Although conventional cytotoxic chemotherapy remains the standard of care, an ongoing search for novel therapeutic approaches continues. We will highlight several new approaches here, with a particular emphasis on immunotherapeutic strategies. We will also introduce concepts regarding the potential economic effects associated with the development and implementation of new treatments in pancreatic cancer.",
author = "Daniel Ahn and Ko, {Andrew H.} and Meropol, {Neal J.} and Tanios Bekaii-Saab",
year = "2015",
month = "1",
day = "1",
doi = "10.14694/EdBook_AM.2015.35.e222",
language = "English (US)",
pages = "e222--e227",
journal = "American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting",
issn = "1548-8756",
publisher = "American Society of Clinical Oncology",

}

TY - JOUR

T1 - Making sense of current and emerging therapies in pancreatic cancer

T2 - balancing benefit and value

AU - Ahn, Daniel

AU - Ko, Andrew H.

AU - Meropol, Neal J.

AU - Bekaii-Saab, Tanios

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Pancreatic cancer remains the fourth leading cause of cancer deaths in the United States with a dismal prognosis and a 5-year survival of less than 5% across all stages.(1) In 2014, there were approximately 46,420 new cases of pancreatic cancer with only 9% of patients having localized disease.(2) Given that the vast majority of patients present with advanced disease, much of the focus for drug development has been in the metastatic setting, which is evident with the advent of two combination chemotherapy regimens for this indication. Although conventional cytotoxic chemotherapy remains the standard of care, an ongoing search for novel therapeutic approaches continues. We will highlight several new approaches here, with a particular emphasis on immunotherapeutic strategies. We will also introduce concepts regarding the potential economic effects associated with the development and implementation of new treatments in pancreatic cancer.

AB - Pancreatic cancer remains the fourth leading cause of cancer deaths in the United States with a dismal prognosis and a 5-year survival of less than 5% across all stages.(1) In 2014, there were approximately 46,420 new cases of pancreatic cancer with only 9% of patients having localized disease.(2) Given that the vast majority of patients present with advanced disease, much of the focus for drug development has been in the metastatic setting, which is evident with the advent of two combination chemotherapy regimens for this indication. Although conventional cytotoxic chemotherapy remains the standard of care, an ongoing search for novel therapeutic approaches continues. We will highlight several new approaches here, with a particular emphasis on immunotherapeutic strategies. We will also introduce concepts regarding the potential economic effects associated with the development and implementation of new treatments in pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=84965185427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965185427&partnerID=8YFLogxK

U2 - 10.14694/EdBook_AM.2015.35.e222

DO - 10.14694/EdBook_AM.2015.35.e222

M3 - Review article

C2 - 25993177

AN - SCOPUS:84965185427

SP - e222-e227

JO - American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

JF - American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

SN - 1548-8756

ER -